Immunome, Inc. filings document the company’s targeted oncology business, public-company governance, capital structure, and material event disclosures. Its 8-K reports cover operating results, business updates, clinical and regulatory communications for programs such as varegacestat and IM-1021, investor presentations, and equity financing activity involving its common stock.
Proxy materials describe board matters, stockholder voting items, executive compensation, equity plans, and governance practices. The filing record also reflects Nasdaq-listed common stock, stock-based compensation arrangements, and formal disclosures tied to the development of antibody-drug conjugates, gamma secretase inhibition, and FAP-targeted radiotherapy within Immunome’s oncology pipeline.
Immunome, Inc. (IMNM) amended its license agreement with Bristol-Myers Squibb Company (BMS) on October 2, 2026. In exchange for $20.0 million in cash and 4,425,487 common shares, Immunome obtained patent rights related to varegacestat (formerly AL102) and AL101, previously licensed under the agreement. The amendment removes milestone and royalty payments; after paying the consideration, Immunome has no milestone, royalty or other payment obligations to BMS under the agreement or amendment.
Under a concurrent stock issuance agreement, Immunome agreed to use commercially reasonable efforts to file a resale registration statement registering the shares for resale by BMS by November 16, 2026. It also agreed to cause the statement to be declared effective as soon as practicable, no later than 60 calendar days after filing or 5 business days after notice that the SEC will not review the statement or that it will not be subject to further review.
Immunome Inc. (IMNM) reported that Chief Scientific Officer Jack Higgins exercised options for 18,000 shares of common stock on September 11, 2026 at an exercise price of $1.35 per share, resulting in 133,840 options remaining outstanding under this grant. On the same date, he sold 13,200 shares of common stock at an average price of $25.32 per share pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2025, and made a bona fide gift of 8,800 shares. In addition, three custodial accounts for his children each hold 1,000 shares, for which he serves as custodian and disclaims beneficial ownership.
Immunome Inc. (IMNM) received a notice that Jack P. Higgins plans to sell up to 13,200 shares of common stock under Rule 144, with Fidelity Brokerage Services LLC acting as broker. The shares relate to a stock option exercise from September 10, 2025, paid in cash.
The filing lists Immunome common stock as quoted on NASDAQ and reports 113,577,629 shares of common stock outstanding, serving as the baseline for this planned sale.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 19,676,883 shares of Immunome, Inc. common stock, representing 17.4% of the class. It has sole voting power over 19,656,814 shares and sole dispositive power over 19,676,883 shares, with no shared voting or dispositive power.
The shares are held for advisory clients, who retain the right to receive dividends and sale proceeds, and may revoke delegated authority. The T. Rowe Price Small-Cap Stock Fund has an interest in 7,179,563 shares, representing 6.5% of Immunome’s common stock. T. Rowe Price Investment Management expressly denies beneficial ownership beyond this reporting capacity.
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of Immunome Inc. common stock. They collectively hold 4,832,279 shares of common stock, representing 4.3% of the class, based on 113,250,394 shares outstanding as of May 7, 2026.
The Reporting Persons have shared voting and dispositive power over all 4,832,279 shares and no sole voting or dispositive power. Sirenia is a Delaware limited partnership, and Mr. Silverstein is a U.S. citizen. This amended Schedule 13G reflects ownership of 5% or less of Immunome’s outstanding common stock.
Immunome Inc. director Isaac Barchas reported three open-market sales of common stock totaling 83,464 shares in August 2026. On August 12, he directly sold 11,048 shares at $27.25 per share, leaving 92,211 shares held directly. On August 10 and 11, entities associated with him, including ABHMC II LLC, sold 10,125 and 62,291 shares, respectively; he disclaims beneficial ownership of those shares except for any pecuniary interest. All reported sales occurred automatically under Rule 10b5-1 trading plans adopted on March 31, 2026.
Immunome, Inc. continued to operate as a clinical‑stage oncology biotech with no product revenue and a growing R&D footprint in the quarter ended June 30, 2026. The company reported a Q2 2026 net loss of $73.1 million and a six‑month net loss of $127.0 million, both wider than a year earlier, driven by higher research and development and commercialization‑readiness spending. Q2 collaboration revenue fell to zero after the AbbVie agreement ended in 2025.
Cash, cash equivalents and marketable securities totaled $520.0 million at June 30, 2026, with management stating this should fund current and planned operations for at least 12 months from the report’s filing date. Operating cash outflow was $120.3 million for the first half of 2026. The pipeline advanced, with varegacestat’s NDA accepted by the FDA and assigned an April 28, 2027 PDUFA date, and multiple antibody‑drug conjugate and radioligand programs in Phase 1 trials or IND‑enabling work.
Immunome, Inc. reported second quarter 2026 results and highlighted major oncology pipeline progress. Varegacestat advanced with U.S. FDA acceptance of its New Drug Application for adults with desmoid tumors and a PDUFA target action date of April 28, 2027, following positive Phase 3 RINGSIDE data that showed an 84% reduction in risk of disease progression or death versus placebo and higher objective response rates.
The company dosed first patients in 2026 Phase 1 trials for IM-1617, a solid tumor antibody-drug conjugate, and IM-3050, a FAP-targeted radioligand therapy, while the IM-1021 Phase 1 trial continues with objective responses in B-cell lymphoma. As of June 30, 2026, Immunome held $520.0 million in cash, cash equivalents and marketable securities and expects this to fund operations into 2028. For the quarter, there was no collaboration revenue compared with $4.0 million a year earlier, operating expenses increased, and the company recorded a net loss of $73.1 million.
Immunome Inc. director Isaac Barchas reported indirect sales of Immunome common stock executed by AMBHMC II LLC ("ABHMC"), an entity he helps manage. On August 6 and 7, 2026, ABHMC sold a total of 36,088 shares of common stock in open market or private transactions at a weighted average price of $26.06 per share, with price ranges between $26.00 and $26.3318 depending on the trade. These sales occurred automatically under a Rule 10b5-1 trading plan adopted by ABHMC on March 31, 2026. Barchas reports that ABHMC owns the shares and disclaims beneficial ownership except to the extent of any pecuniary interest. A separate line reports 103,259 shares of Immunome common stock held directly by Barchas as of August 6, 2026.